课题基金 / 基金详情

Mutation-targeted gene and pharmacological therapies for dystrophic and junctional Epidermolysis Bullosa

Mutation-targeted gene and pharmacological therapies for dystrophic and junctional Epidermolysis Bullosa
营养不良性和交界性大疱性表皮松解症的突变靶向基因和药物疗法
批准号:
367021
负责人:
Roberge Michel
金额:
$22.25万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2017
资助国家:
加拿大
项目状态:
已结题
起止时间:
2017-06-01 至 2020-06-01

项目摘要

项目成果

Roberge Michel的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Translating new experimental therapies for rare diseases to the clinic remains a formidable challenge. New, innovative, safe and efficacious approaches to restore expression of adhesive skin proteins in epidermolysis bullosa (EB) patients are needed. Sup
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Preclinical evaluation of a gentamicin analog as a treatment for genetic diseases and cancer due to a premature termination codon.
  • 批准号:
    335020
  • 项目类别:
    Operating Grants
  • 资助金额:
    $10.93万
  • 财政年份:
    2015
  • 负责人:
    Roberge Michel
  • 依托单位:
Preclinical Development of a novel M2 Channel Inhibitor for the Treatment and Prevention of Influenza
  • 批准号:
    293922
  • 项目类别:
    Operating Grants
  • 资助金额:
    $11.66万
  • 财政年份:
    2013
  • 负责人:
    Roberge Michel
  • 依托单位:
Evaluation of the anticancer activity of a new autophagy-inhibitory drug
  • 批准号:
    194925
  • 项目类别:
    Operating Grants
  • 资助金额:
    $10.42万
  • 财政年份:
    2009
  • 负责人:
    Roberge Michel
  • 依托单位:
海外基金